Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study

Clinical Therapeutics

Volumn 26, Issue 5, 2004, Pages 694-703

  Majumdar, Sumit R ^a   McAlister, Finlay A ^a   Cree, Marilyn ^b   Chang, Wei Ching ^a,b   Packer, Milton ^c   Armstrong, Paul W ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Virtual Coordinating Center for Global Collaborative Cardiovascular Research   (Canada)

^c Columbia University ^*  (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Beta blockers; Congestive heart failure; Digoxin; Evidence based medicine; Guideline adherence; Polypharmacy

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; RANDOMIZATION; TREATMENT OUTCOME;

EID: 2942609162     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(04)90069-0     Document Type: Article

References (29)

1. McAlister FA, Teo KK, Taher M, et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J. 1999; 138:87-94.
2. Bungard TJ, McAlister FA, Johnson JA, Tsuyuki RT. Underutilization of ACE inhibitors in patients with congestive heart failure. Drugs. 2001;61:2021-2033.
3. Pulignano G, Del Sindaco D, Tavazzi L, et al, for the IN-CHF Investigators. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: Data from a large nationwide cardiology database (IN-CHF Registry). Am Heart J. 2002;143:45-55.
4. Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction: Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J. 1999;20:1182-1190.
5. Nohria A, Chen YT, Morton DJ, et al. Quality of care for patients hospitalized with heart failure at academic medical centers. Am Heart J. 1999;137:1028-1034.
6. Philbin EF, Rocco TA Jr, Lindenmuth NW, et al. Clinical outcomes in heart failure: Report from a community hospital-based registry. Am J Med. 1999;107: 549-555.
7. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med. 2002;113:650-656.
8. Jong P, Vowinckel E, Liu PP, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: A population-based study. Arch Intern Med. 2002;162:1689-1694.
9. Garg R, Yusuf S, for the Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure [published correction appears in JAMA. 1995;274:462]. JAMA. 1995;273:1450-1456.
10. Packer M, Poole-Wilson PA, Armstrong PW, et al, for the ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312-2318.
11. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med. 2001;134:550-560.
12. Wikstrand J, Hjalmarson A, Waagstein F, et al, for the MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: Analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002;40:491-498.
13. Bristow MR, Gilbert EM, Abraham WT, et al, for the Multicenter Oral Carvedilol Heart Failure Assessment (MOCHA) Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807-2816.
14. The Digitalis Investigation Group, The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525-533.
15. Packer M. End of the oldest controversy in medicine. Are we ready to conclude the debate on digitalis? N Engl J Med. 1997;336:575-576.
16. Hood WB, Dans AL, Guyatt GH, et al. Digitalis for the treatment of congestive heart failure in patients in sinus rhythm (Cochrane Review). In: Cochrane Library, 2002. Oxford: Update Software.
17. Adams KF Jr, Gheorghiade M, Uretsky BF, et al. Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol. 2002;39:946-953.
18. van Veldhuisen DJ. Low-dose digoxin in patients with heart failure. Less toxic and at least as effective? J Am Coll Cardiol. 2002;39:954-956.
19. Liu P. The 2001 Canadian Cardiovascular Society Consensus Guideline Update for the Management and Prevention of Heart Failure. Available at: http://www.ccs.ca/society/conferences/archives/2001update/2001coneng-01.cfm. Accessed December 19, 2003.
20. Hunt HA, Baker DW, Chin MH, et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure). Circulation. 2001;104:2996-3007.
21. Remme WJ, Swedberg K, for the Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527-1560.
22. McMurray J, Cohen-Solal A, Dietz R, et al, for Clinical Research Initiative in Heart Failure. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: Putting guidelines into practice. Eur J Heart Fail. 2001;3:495-502.
23. McMurray J, Pfeffer MA. New therapeutic options in congestive heart failure. Part II. Circulation. 2002;105: 2223-2228.
24. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
25. Greenberg BH. Angiotensin receptor blockers in heart failure: A work in progress. J Am Coll Cardiol. 2002;40: 1422-1424.
26. Pfeffer MA, Swedberg K, Granger CB, et al, for the Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet. 2003;362:759-766.
27. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA. 1999;282:790-795.
28. Skali H, Solomon SD, Pfeffer MA. Are we asking too much of our trials? Am Heart J. 2002;143:1-3.
29. Pitt B, Zannad F, Remme WJ, et al, for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.